

Research article

Open Access

## Association between promoter -1607 polymorphism of *MMP1* and Lumbar Disc Disease in Southern Chinese

You-Qiang Song<sup>†1,2</sup>, Daniel WH Ho<sup>†1</sup>, Jaro Karppinen<sup>3</sup>, Patrick YP Kao<sup>1</sup>, Bao-Jian Fan<sup>1</sup>, Keith DK Luk<sup>2</sup>, Shea-Ping Yip<sup>4</sup>, John CY Leong<sup>6</sup>, Kathryn SE Cheah<sup>1</sup>, Pak Sham<sup>5</sup>, Danny Chan<sup>1</sup> and Kenneth MC Cheung<sup>\*2</sup>

Address: <sup>1</sup>Department of Biochemistry, University of Hong Kong, Hong Kong, China, <sup>2</sup>Department of Orthopaedics and Traumatology, University of Hong Kong, Hong Kong, China, <sup>3</sup>Department of Rehabilitation, University of Oulu, Oulu, Finland, <sup>4</sup>Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China, <sup>5</sup>Department of Psychiatry, University of Hong Kong, Hong Kong, China and <sup>6</sup>Open University of Hong Kong, Hong Kong, China

Email: You-Qiang Song - songy@hku.hk; Daniel WH Ho - dwhho@hku.hk; Jaro Karppinen - jaro.karppinen@ttl.fi; Patrick YP Kao - patrickkao@hku.hk; Bao-Jian Fan - bao-jian\_fan@meei.harvard.edu; Keith DK Luk - hrmoldk@hku.hk; Shea-Ping Yip - htspyp@smtp7.polyu.edu.hk; John CY Leong - jycleong@ouhk.edu.hk; Kathryn SE Cheah - hrmbdkc@hkusua.hku.hk; Pak Sham - pcsham@hku.hk; Danny Chan - chand@hkusua.hku.hk; Kenneth MC Cheung\* - cheungmc@hku.hk

\* Corresponding author †Equal contributors

Published: 28 April 2008

Received: 30 November 2007

BMC Medical Genetics 2008, 9:38 doi:10.1186/1471-2350-9-38

Accepted: 28 April 2008

This article is available from: <http://www.biomedcentral.com/1471-2350/9/38>

© 2008 Song et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Matrix metalloproteinases (MMPs) are involved in the degradation of the extracellular matrix of the intervertebral disc. A SNP for guanine insertion/deletion (G/D), the -1607 promoter polymorphism, of the *MMP1* gene was found significantly affecting promoter activity and corresponding transcription level. Hence it is a good candidate for genetic studies in DDD.

**Methods:** Southern Chinese volunteers between 18 and 55 years were recruited from the population. DDD in the lumbar spine was defined by MRI using Schneiderman's classification. Genomic DNA was isolated from the leukocytes and genotyping was performed using the Sequenom<sup>®</sup> platform. Association and Hardy-Weinberg equilibrium checking were assessed by Chi-square test and Mann-Whitney U test.

**Results:** Our results showed substantial evidence of association between -1607 promoter polymorphism of *MMP1* and DDD in the Southern Chinese subjects. D allelic was significantly associated with DDD (p value = 0.027, odds ratio = 1.41 with 95% CI = 1.04–1.90) while Genotypic association on the presence of D allele was also significantly associated with DDD (p value = 0.046, odds ratio = 1.50 with 95% CI = 1.01–2.24). Further age stratification showed significant genotypic as well as allelic association in the group of over 40 years (genotypic: p value = 0.035, odds ratio = 1.617 with 95% CI = 1.033–2.529; allelic: p value = 0.033, odds ratio = 1.445 with 95% CI = 1.029–2.029). Disc bulge, annular tears and the Schmorl's nodes were not associated with the D allele.

**Conclusion:** We demonstrated that individuals with the presence of D allele for the -1607 promoter polymorphism of *MMP1* are about 1.5 times more susceptible to develop DDD when compared with those having G allele only. Further association was identified in individuals over 40 years of age. Disc bulge, annular tear as well as Schmorl's nodes were not associated with this polymorphism.

## Background

Low back pain (LBP) affects 70% to 80% of all people at some time during their life [1]. The annual prevalence ranges from 15% to 45%, with a point prevalence averaging 30% [1]. Degenerative Disc Disease (DDD) in the lumbar spine or lumbar disc degeneration is a major cause of LBP [2-7].

Up to now, there is only a limited understanding of DDD, with the underlying pathophysiological and molecular mechanisms remain un-elucidated. Studies suggested that environmental factors such as physical loading, motor vehicle driving, vibration and smoking may have a role [8-11]. However, there is increasing evidence that DDD is a genetic disorder [12], with reports of predisposition in association with certain genes, such as *Taq I* polymorphism of vitamin D receptor (*VDR*) gene [2,5,13,14], polymorphism of metalloproteinase-3 (*MMP3*) gene [15-17], mutations in collagen IX genes (*COL9A2* and *COL9A3*) [18-22], Sp1 polymorphism of collagen I gene (*COL1A1*) [23,24], polymorphism of cartilage intermediate layer protein (*CILP*) [25] as well as aggrecan gene polymorphism [26]. The involvement of multiple genes is not uncommon, as aetiology is often multifactorial in common diseases such as DDD [12].

In the process of disc degeneration, degradation of the extracellular matrix (ECM) is a key event. Collagens are one of the major constituents of the ECM. They make up 20% dry mass of the nucleus pulposus and 60% dry mass of the annulus fibrosus. Approximately 80% of the collagens in the intervertebral disc consist of fibrillar collagen types I and II [16,27]. Matrix metalloproteinases (MMPs) are the family of degradation enzymes that break down the components of the ECM [17,27,28]. In particular, MMP1 is a collagenase which cleaves the triple helical part of the fibrillar collagen of types I, II and III, and is proposed to initiate the degradation process [29-35]. The cleaved fragments have a lower melting temperature than 37°C, which are then further cleaved by other MMPs. Similarly, MMP1 can cleave aggrecan at the major MMP cleavage sites between the G1 and G2 domains contributing to the breakdown of aggrecan [36].

Expression of MMPs is generally low in normal cells which allows for healthy tissue turnover. On the other hand, the level of MMPs increases substantially under pathological conditions and results in ECM degradation. A single nucleotide polymorphism (SNP) for guanine insertion/deletion (G/D) at position -1607 in the promoter region of the *MMP1* gene (-1607 polymorphism) results in creation of binding sites for Ets transcription factor family [29]. Upon the interaction of adjacent AP-1 site, the promoter activity and hence the transcription level of *MMP1* can be considerably increased [29,30].

In the present study, the association between this promoter SNP and DDD was investigated in a population-based dataset [14,22]. We demonstrated significant association with DDD and the deletion of guanine is suggested to be a possible genetic risk factor predisposing to DDD.

## Methods

### Subjects & assessment

The study was approved by the local ethics committee and informed consent was obtained. Individuals of Southern Chinese origin were recruited by open invitation from the general population. All the recruited subjects subsequently underwent magnetic resonance imaging (MRI) of the lumbar spine and their blood was obtained for DNA extraction and genotyping analysis.

The MRI examinations were performed at the Jockey Club MRI Engineering Centre using a 0.2T Profile open MRI system (General Electric Medical System, Milwaukee, WI). Sagittal T2-weighted fast spin echo sequences (TR = 3000 ms, TE = 92 ms, slice thickness = 5 mm) were used to image the lumbar spine with a built-in flexible body coil. Despite the relative low field, previous studies have demonstrated this to be sensitive enough to identify abnormalities associated with DDD [14,22].

DDD was diagnosed on the basis of signal intensity changes within the nucleus pulposus (NP) of the intervertebral discs (IVDs) of the lumbar spine and graded using the Schneiderman's classification scheme [37]. Grade 0 was used to indicate normal disc with hyperintense signal within the NP, grade 1 for a slight decrease in signal intensity in the NP, grade 2 for a generalized hypointense NP and grade 3 for a hypointense NP with disc space narrowing. All the MRI scans were analyzed and rated by two experienced physicians blinded to the results of the genetic analysis and clinical history. Differences were reviewed by the two raters and settled by consensus. The score for each disc (0-3) was then summated to create a DDD score for the whole lumbar spine (0-15) as previously described [14]. To define the affection status using DDD score, a score of 0 was used to indicate the absence of disc degeneration, while a score of 2 or above was used to indicate the presence of degeneration. Individuals with DDD score of 1 are considered as borderline degeneration and was the area of the majority of disagreements between the 2 raters and hence those with DDD score of 1 was considered unknown affection status and excluded from analysis [14,22].

Disc bulge was defined in discs where it has protruded posteriorly beyond a line connecting the posterior margins of the adjacent vertebral bodies. In addition, annular tears and Schmorl's nodes were assessed [14]. Annular

tears were defined as areas of high signal intensity within the posterior annulus surrounded by a dark rim. Schmorl's nodes were defined as areas of endplate irregularities in which the darkened rim of the vertebral endplate has indented into the vertebral body.

**SNP genotyping**

Genomic DNA was isolated from the leukocytes and the quality as well as quantity measured by spectrophotometry. Genotyping was performed using the Sequenom® platform. The Mass ARRAY AssayDesign software (Sequenom) was used to design amplification and allele-specific extension primers. The extension primer (5'-GTAGTTAAATAATTAGAAAG-3') was designed to hybridize to the amplicon near the SNP site for the extension of a single base or a few bases depending on the genotype of the allele. PCR reactions (Forward primer: 5'-ACGTTGGATGGAACCTCACATGTTATGCCAC-3'; Reverse-primer: 5'-ACGTTGGATGCCTCAGTATATCTTGGATTG-3') were set up in 384-well plates at 6 µL total volume per reaction and the reaction mix contains: 5 ng genomic DNA, 0.3 pmol each of specific forward and reverse primers, 200 µM of each dNTP, 3.25 mM MgCl<sub>2</sub> and 0.2 unit of Hot-StarTaq polymerase (5U/µL, Qiagen, Valencia, CA). The PCR condition was: 95°C for 15 min, 45 cycles of 95°C for 20 sec, 56°C for 30 sec and 72°C for 1 min, followed by 72°C for 3 min. The treatment of PCR products with alkaline phosphatase and mass extend reactions were all performed according to manufacturer's (Sequenom) protocol. The final base-extension products were desalted using SpectroClean resin (Sequenom), mixed with 3-hydroxypicolinic acid and analyzed using a modified Bruker Autoflex MALDI-TOF mass spectrometer (Bruker, Billerica, MA).

**Statistical analysis**

Association and Hardy-Weinberg equilibrium checking were assessed by  $\chi^2$  test and Mann-Whitney U test. Odds ratios and other statistical measures were calculated by SPSS 14.0 software.

**Results**

A total of 691 individuals were genotyped for the study with 266 males and 425 females. In common with previ-

ous studies, no significant differences could be detected in disease predisposition between the 2 genders and therefore no gender stratification was carried out [11,13,14].

Analysis of the D allele showed an over representation in the case group. The D allele conferred a higher risk (1.4 times) of developing DDD when compared to the G allele (*P*-value = 0.027, odds ratio = 1.41 with 95% CI = 1.04–1.90) (Table 1). Genotypic association on the presence of the D allele was also significantly associated with DDD (*P*-value = 0.046, odds ratio = 1.50 with 95% CI = 1.01–2.24) (Table 2).

Because DDD is age related and 2 risk factors, *VDR* [14] and the *COL9A2* [22], have previously been demonstrated to be age-dependent, we also analyzed this *MMP1* association to DDD stratified by age group. Using a stratification as in a previous study [14], no significant association was detected in an under-40-year age group (*P*-value = 0.5, OR = 1.26 with 95% CI = 0.64–2.46). However, in the over-40-year age group, the association was significant (*P*-value = 0.03, OR = 1.46 with 95% CI = 1.03–2.03) (Tables 1 & 2).

In addition, we assessed the difference in the distribution of the DDD score for the D-allele+ (either DD or DG genotype) and D-allele- (GG genotype) groups by Mann-Whitney U test. It was found that the distribution of the DDD score was significantly different between the D-allele+ and D-allele- groups (*p* value = 0.028) with D-allele+ group having higher DDD score.

Apart from DDD, association was tested on disc bulge, annular tear as well as Schmorl's nodes, no significant association with these phenotypes were found with the *MMP1* promoter polymorphism (Table 3).

**Discussion**

This is the first report of an association of a SNP in the promoter region of *MMP1* with DDD. DDD is a complex multifactorial disease. It has been suggested that disc degeneration is highly correlated to age [15,38-41] and age stratification was performed in previous studies [14,22]. Our results indicated that the association of DDD

**Table 1: Allelic association of DDD with the -1607 polymorphism of MMP1**

	Total		Age ≤ 40		Age > 40	
	G (%)	D (%)	G (%)	D (%)	G (%)	D (%)
Control	170 (69.7)	74 (30.3)	31 (67.4)	15 (32.6)	139 (70.2)	59 (29.8)
Case	593 (62.0)	363 (38.0)	143 (62.2)	87 (37.8)	450 (62.0)	276 (38.0)
OR (95% CI)	1.41 (1.04–1.90)		1.26 (0.64–2.46)		1.46 (1.03–2.03)	
<i>p</i> value	0.027		0.503		0.033	

Note: The G allele is the reference allele of the calculation of ORs.

**Table 2: Genotypic association of LDD with the -1607 polymorphism of MMP1**

	Total		Age ≤ 40		Age > 40	
	GG (%)	DD/DG (%)	GG (%)	DD/DG (%)	GG (%)	DD/DG (%)
Control	58 (47.5)	64 (52.5)	9 (39.1)	14 (60.9)	49 (49.5)	50 (50.5)
Case	180 (37.7)	298 (62.3)	43 (37.4)	72 (62.6)	137 (37.7)	226 (62.3)
OR (95% CI)	1.50 (1.01–2.24)		1.08 (0.43–2.70)		1.62 (1.03–2.53)	
p value	0.046		0.875		0.035	

Note: The GG genotype is reference genotype of the calculation of ORs.

with the SNP is age-dependent, and is associated with subjects over 40 years of age.

MMP1 is involved in the cleavage of fibrillar collagens I, II and III [29-35]. Type I collagen is found extensively within the annulus fibrosus and bony end-plate, while Type II is the predominant collagen in the inner annulus, nucleus pulposus as well as the cartilaginous end-plate [16,27]. Previous studies in tumor cell lines showed that an over-representation of the G allele of this promoter SNP resulted in increased MMP1 transcriptional activity, hence more aggressive matrix degradation [29]. This was proposed to be a mechanism in cancer progression and was proven in subsequent functional studies which showed that the G allele created additional binding sites for the Ets family of transcription factors [29]. These Ets binding sites (-1607 bp) work cooperatively with a nearby AP-1 site (-1602 bp) to enhance promoter activity by at least 2 folds [29,30]. With the increased promoter activity and hence transcription level, the presence of the G allele could consider to be risk factor for matrix degradation.

Although we found an association with this promoter SNP in MMP1, our result showed the presence of the D allele resulted in an increased risk of DDD, and not the anticipated G allele. Previous *in vitro* studies have shown that the G allele is associated with higher expression levels of MMP1 [29,30]. Thus, individuals with the D allele with increase risk for DDD could not be explained by increased susceptibility to matrix degradation because there is no over-expression of MMP1.

**Table 3: Genotypic association of other degenerative changes with the -1607 polymorphism of MMP1**

		GG (%)	DD/DG (%)	p value
Disc bulge	Control	122 (42.7)	164 (57.3)	0.316
	Case	113 (38.6)	180 (61.4)	
Annular tear	Control	215 (41.0)	309 (59.0)	0.430
	Case	55 (37.4)	92 (62.6)	
Schmorl's node	Control	239 (40.0)	358 (60.0)	0.758
	Case	31 (41.9)	43 (58.1)	

This association may be explained in a number of ways. First, the frequency for D allele is high in different ethnic populations with 62.5% and 56.7% for African and Caucasian respectively (NCBI database), and 36.4% for Southern Chinese. The high frequency of D allele may indicate that the D allele is a common ancestor allele, which might be in linkage disequilibrium with unknown disease-causing polymorphism within the same gene. Secondly, MMP1 is located in a gene cluster on chromosome 11 with other MMP genes (MMP-3, 7, 8, 10, 12, 13, 20 and 26). It is possible that the observed association is the result of linkage disequilibrium between this MMP1 promoter polymorphism and polymorphisms in other nearby MMP genes. Moreover, despite the Ets binding site can cooperate with AP-1 site to enhance transcription of MMP1, this polymorphism has yet to be tested in intervertebral disc tissues, to see whether it affects the transcription level of MMP1. It maybe that gene expression be differentially displayed in a tissue-specific manner. In addition, expressional activity of MMP1 may also be influenced differentially in response to cytokines and growth factors. Even in the case of cancer, allele corresponding to elevated MMP1 activity (expected to have increased susceptibility to cancer and poor prognosis) was unexpectedly found to have favourable prognosis with colorectal cancer and no association with tumor characteristics [42]. Thus further replications of association in other ethnic populations would help substantiate findings in this study.

**Conclusion**

In summary, we have performed a case-control association study to test for association between this promoter SNP (-1607 polymorphism) of MMP1 and DDD. We have demonstrated this promoter polymorphism was significantly associated with increased susceptibility to DDD in our Southern Chinese population, especially in individuals over 40 years of age. Disc bulge, annular tear as well as Schmorl's nodes were not associated with this polymorphism.

**Competing interests**

The authors declare that they have no competing interests.

## Authors' contributions

YQ, DW, PYP and BJ carried out molecular studies. YQ, DW and KMC drafted the manuscript. JK, KMC, KDK and JCY carried out clinic studies. DW, SPY and PS performed the statistical analysis. YQ, KSE, DC and KMC conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

## Acknowledgements

The authors thank Pei Yu, Woo Yuk Kuen, Mavis Yiu, and Iris Lee for their expert technical assistance. The authors also thank The Hong Kong Jockey Club MRI Center and the Genome Research Centre, The University of Hong Kong for the use of their facilities. This work was supported by grants from the University Grants Committee of Hong Kong (AoE/M-04/04) and the Research Grants Council of Hong Kong (HKU7509/03 M).

## References

- Andersson GB: **Epidemiological features of chronic low-back pain.** *Lancet* 1999, **354**:581-585.
- Kawaguchi Y, Kanamori M, Ishihara H, Ohmori K, Matsui H, Kimura T: **The association of lumbar disc disease with vitamin-D receptor gene polymorphism.** *J Bone Joint Surg Am* 2002, **84-A(11)**:2022-2028.
- Salminen JJ, Erkkintalo MO, Pentti J, Oksanen A, Kormano MJ: **Recurrent low back pain and early disc degeneration in the young.** *Spine* 1999, **24**:1316-1321.
- Rannou F, Revel M, Poiraudou S: **Is degenerative disk disease genetically determined?** *Joint Bone Spine* 2003, **70**:3-5.
- Videman T, Leppavuori J, Kaprio J, Battie MC, Gibbons LE, Peltonen L, Koskenvuo M: **Intragenic polymorphisms of the vitamin D receptor gene associated with intervertebral disc degeneration.** *Spine* 1998, **23**:2477-2485.
- Deyo RA, Weinstein JN: **Low back pain.** *N Engl J Med* 2001, **344**:363-370.
- Oegema TR Jr, Johnson SL, Aguiar DJ, Ogilvie JW: **Fibronectin and its fragments increase with degeneration in the human intervertebral disc.** *Spine* 2000, **25**:2742-2747.
- Kelsey JL, Githens PB, O'Conner T, Weil U, Calogero JA, Holford TR, White AA 3rd, Walter SD, Ostfeld AM, Southwick WO: **Acute prolapsed lumbar intervertebral disc. An epidemiologic study with special reference to driving automobiles and cigarette smoking.** *Spine* 1984, **9**:608-613.
- Ishihara H, Tsuji H, Hirano N, Ohshima H, Terahata N: **Effects of continuous quantitative vibration on rheologic and biological behaviors of the intervertebral disc.** *Spine* 1992, **17(3 Suppl)**:S7-12.
- Pope MH, Hansson TH: **Vibration of the spine and low back pain.** *Clin Orthop Relat Res* 1992, **279**:49-59.
- Battie MC, Videman T, Gill K, Moneta GB, Nyman R, Kaprio J, Koskenvuo M: **1991 Volvo Award in clinical sciences. Smoking and lumbar intervertebral disc degeneration: an MRI study of identical twins.** *Spine* 1991, **16**:1015-1021.
- Chan D, Song Y, Sham P, Cheung KM: **Genetics of disc degeneration.** *Eur Spine J* 2006, **15**:317-325.
- Videman T, Gibbons LE, Battie MC, Maravilla K, Vanninen E, Leppavuori J, Kaprio J, Peltonen L: **The relative roles of intragenic polymorphisms of the vitamin D receptor gene in lumbar spine degeneration and bone density.** *Spine* 2001, **26(3)**:E7-E12.
- Cheung KM, Chan D, Karppinen J, Chen Y, Jim JJ, Yip SP, Ott J, Wong KK, Sham P, Luk KD, Cheah KS, Leong JC, Song YQ: **Association of the Taq I allele in vitamin D receptor with degenerative disc disease and disc bulge in a Chinese population.** *Spine* 2006, **31**:1143-1138.
- Takahashi M, Haro H, Wakabayashi Y, Kawa-uchi T, Komori H, Shinomiya K: **The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene.** *J Bone Joint Surg Br* 2001, **83**:491-495.
- Guiot BH, Fessler RG: **Molecular biology of degenerative disc disease.** *Neurosurgery* 2000, **47**:1034-1040.
- Roberts S, Caterson B, Menage J, Evans EH, Jaffray DC, Eisenstein SM: **Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc.** *Spine* 2000, **25**:3005-3013.
- Karppinen J, Paakko E, Raina S, Tervonen O, Kurunlahti M, Nieminen P, Ala-Kokko L, Malmivaara A, Vanharanta H: **Magnetic resonance imaging findings in relation to the COL9A2 tryptophan allele among patients with sciatica.** *Spine* 2002, **27**:78-83.
- Paasilta P, Lohiniva J, Goring HH, Perala M, Raina SS, Karppinen J, Hakala M, Palm T, Kroger H, Kaitila I, Vanharanta H, Ott J, Ala-Kokko L: **Identification of a novel common genetic risk factor for lumbar disk disease.** *JAMA* 2001, **285**:1843-1849.
- Annunen S, Paasilta P, Lohiniva J, Perala M, Pihlajamaa T, Karppinen J, Tervonen O, Kroger H, Lahde S, Vanharanta H, Ryhnen L, Goring HH, Ott J, Prockop DJ, Ala-Kokko L: **An allele of COL9A2 associated with intervertebral disc disease.** *Science* 1999, **285**:409-412.
- Solovieva S, Lohiniva J, Leino-Arjas P, Raininko R, Luoma K, Ala-Kokko L, Riihimaki H: **COL9A3 gene polymorphism and obesity in intervertebral disc degeneration of the lumbar spine: evidence of gene-environment interaction.** *Spine* 2002, **27**:2691-2696.
- Jim JJ, Noponen-Hietala N, Cheung KM, Ott J, Karppinen J, Sahravand A, Luk KD, Yip SP, Sham PC, Song YQ, Leong JC, Cheah KS, Ala-Kokko L, Chan D: **The TRP2 allele of COL9A2 is an age-dependent risk factor for the development and severity of intervertebral disc degeneration.** *Spine* 2005, **30**:2735-2742.
- Pluijms SM, van Essen HW, Bravenboer N, Uitterlinden AG, Smit JH, Pols HA, Lips P: **Collagen type I alpha S1 polymorphism, osteoporosis, and intervertebral disc degeneration in older men and women.** *Ann Rheum Dis* 2004, **63**:71-77.
- Tilkeridis C, Bei T, Garantziotis S, Stratakis CA: **Association of a COL1A1 polymorphism with lumbar disc disease in young military recruits.** *J Med Genet* 2005, **42**:e44.
- Seki S, Kawaguchi Y, Chiba K, Mikami Y, Kizawa H, Oya T, Mio F, Mori M, Miyamoto Y, Masuda I, Tsunoda T, Kamata M, Kubo T, Toyama Y, Kimura T, Nakamura Y, Ikegawa S: **A functional SNP in COL1A1 encoding cartilage intermediate layer protein, is associated with susceptibility to lumbar disc disease.** *Nat Genet* 2005, **37**:607-612.
- Kawaguchi Y, Osada R, Kanamori M, Ishihara H, Ohmori K, Matsui H, Kimura T: **Association between an aggrecan gene polymorphism and lumbar disc degeneration.** *Spine* 1999, **24**:2456-2460.
- Goupille P, Jayson MI, Valat JP, Freemont AJ: **Matrix metalloproteinases: the clue to intervertebral disc degeneration?** *Spine* 1998, **23**:1612-1626.
- Grange L, Gaudin P, Trocme C, Phelip X, Morel F, Juvin R: **Intervertebral disk degeneration and herniation: the role of metalloproteinases and cytokines.** *Joint Bone Spine* 2001, **68**:547-553.
- Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE: **A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription.** *Cancer Res* 1998, **58**:5321-5325.
- Fujimoto T, Parry S, Urbanek M, Sammel M, Macones G, Kuivaniemi H, Romero R, Strauss JF 3rd: **A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes.** *J Biol Chem* 2002, **277**:6296-6302.
- Vincenti MP, Brinckerhoff CE: **Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.** *Arthritis Res* 2002, **4(3)**:157-64.
- Matsui Y, Maeda M, Nakagami W, Iwata H: **The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation.** *Spine* 1998, **23(8)**:863-8.
- Tower GB, Coon CI, Belguise K, Chablos D, Brinckerhoff CE: **Fra-I targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter.** *Eur J Biochem* 2003, **270(20)**:4216-25.
- Benbow U, Tower GB, Wyatt CA, Buttice G, Brinckerhoff CE: **High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2**

- mitogen-activated protein kinases in VMM5 melanoma cells.** *J Cell Biochem* 2002, **86(2)**:307-19.
35. Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE: **Erk 1/2 differentially regulates the expression from the IG/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells.** *Biochim Biophys Acta* 2002, **1586(3)**:265-74.
  36. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, Tschesche H, Hamilton JA: **Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.** *Biochem J* 1993, **295**:273-6.
  37. Schneiderman G, Flannigan B, Kingston S, Thomas J, Dillin WH, Watkins RG: **Magnetic resonance imaging in the diagnosis of disc degeneration: correlation with discography.** *Spine* 1987, **12**:276-281.
  38. Powell MC, Wilson M, Szypryt P, Symonds EM, Worthington BS: **Prevalence of lumbar disk degeneration observed by magnetic resonance in symptomless women.** *Lancet* 1986, **2**:1366-1367.
  39. Sether LA, Yu S, Haughton VM, Fischer ME: **Intervertebral disk: normal age-related changes in MR signal intensity.** *Radiology* 1990, **177**:385-388.
  40. Yu SW, Haughton VM, Ho PS, Sether LA, Wagner M, Ho KC: **Progressive and regressive changes in the nucleus pulposus. Part II. The adult.** *Radiology* 1988, **169**:93-97.
  41. Terti M, Paajanen H, Laato M, Aho H, Komu M, Kormanen M: **Disc degeneration in magnetic resonance imaging. A comparative biochemical, histologic, and radiologic study in cadaver spines.** *Spine* 1991, **16**:629-634.
  42. Hettiaratchi A, Hawkins NJ, McKenzie G, Ward RL, Hunt JE, Wakefield D, Girolamo ND: **The collagenase-1 (MMP-1) gene promoter polymorphism -1607/2G is associated with favourable prognosis in patients with colorectal cancer.** *Br J Cancer* 2007, **96**:783-92.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/9/38/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

